Status:
COMPLETED
Pharmacovigilance Study to Evaluate Safety of SERETIDE in Participants With Chronic Obstructive Pulmonary Disease (COPD)
Lead Sponsor:
GlaxoSmithKline
Conditions:
Pulmonary Disease, Chronic Obstructive
Eligibility:
All Genders
Brief Summary
Primary objective: Evaluation of the safety of Seretide discus administration in subjects with COPD. Treatment duration: 2 years. Study has 3 phases: Screening phase (visit 1), treatment phase (visits...
Eligibility Criteria
Inclusion
- Subject should fulfill criteria for the subscription of SERETIDE as these are mentioned in SPC.
Exclusion
- Hypersensitivity to Salmeterol + Fluticasone or any of its excipients
- Pregnancy, lactation or scheduled pregnancy during the observational period of the study
- Serious illness/disease, not adequately controlled, or with a potential to interfere with the patients' participation in the present study, according to the investigator/physician's judgment.
Key Trial Info
Start Date :
June 1 2004
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2008
Estimated Enrollment :
762 Patients enrolled
Trial Details
Trial ID
NCT00662805
Start Date
June 1 2004
End Date
September 1 2008
Last Update
January 20 2014
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.